Earnings

Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies

Oct 14, 2026 · 07:32 AM ET· updated 1h ago

Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on

Why It Matters

Arrowhead's new drug showed it can reach the brain and reduce a harmful protein linked to Alzheimer's. When a medicine first proves it works in patients, that is important proof the company is on the right track.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ARWR60.03

+1.90 (+3.27%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.